Bimoclomol and Arimoclomol: HSP-co-Inducers for the Treatment of Protein Misfolding Disorders, Neuropathy and Neuropathic Pain

New effective and safe treatments for complications of diabetes are clearly needed, and we will discuss in this paper a special group of compounds which stimulate the innate repair and protective mechanisms of our body, via co-inducing Heat Shock Proteins (HSPs). These are the hydroxylamine compounds bimoclomol and arimoclomol which have been consistently found to increase the expression of the molecular chaperones, the HSPs, in cells exposed to a physiological stress. The hydroxylamines are characterized as coinducers of HSPs, because they up-regulate HSP production only in situations of cellular stress responses, for instance induced by diabetes or ischemia, first described in a patent filed in 1996.

Bimoclomol and Arimoclomol
Bimoclomol and Arimoclomol

In this review, we will discuss some findings supporting the use of such compounds to treat complications of diabetes, such as neuropathy and neuropathic pain, with an emphasis on arimoclomol, as this compound is still in clinical development, while the development of its parent compound seems have come to stand still by the end of last century. However, as both compounds have a similar mechanism of action, we will also review data related to bimoclomol.

Advertisements

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s